CN111587975A - 一种改善便秘症状的固体饮料 - Google Patents
一种改善便秘症状的固体饮料 Download PDFInfo
- Publication number
- CN111587975A CN111587975A CN202010281907.5A CN202010281907A CN111587975A CN 111587975 A CN111587975 A CN 111587975A CN 202010281907 A CN202010281907 A CN 202010281907A CN 111587975 A CN111587975 A CN 111587975A
- Authority
- CN
- China
- Prior art keywords
- probiotics
- intestinal
- constipation
- oligosaccharide
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010010774 Constipation Diseases 0.000 title claims abstract description 26
- 208000024891 symptom Diseases 0.000 title claims abstract description 25
- 235000013361 beverage Nutrition 0.000 title claims abstract description 15
- 239000007787 solid Substances 0.000 title claims abstract description 13
- 239000006041 probiotic Substances 0.000 claims abstract description 78
- 235000018291 probiotics Nutrition 0.000 claims abstract description 78
- 230000000694 effects Effects 0.000 claims abstract description 30
- 230000000968 intestinal effect Effects 0.000 claims abstract description 29
- 230000000529 probiotic effect Effects 0.000 claims abstract description 22
- 239000002131 composite material Substances 0.000 claims abstract description 15
- 239000000686 essence Substances 0.000 claims abstract description 8
- 230000003750 conditioning effect Effects 0.000 claims abstract description 7
- 241000894006 Bacteria Species 0.000 claims description 49
- 239000000843 powder Substances 0.000 claims description 34
- 235000013305 food Nutrition 0.000 claims description 24
- 244000105624 Arachis hypogaea Species 0.000 claims description 15
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 15
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 15
- 235000020232 peanut Nutrition 0.000 claims description 15
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 12
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 11
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 11
- 235000018262 Arachis monticola Nutrition 0.000 claims description 11
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 11
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 11
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 11
- 244000199866 Lactobacillus casei Species 0.000 claims description 10
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 10
- 229940017800 lactobacillus casei Drugs 0.000 claims description 10
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 230000033228 biological regulation Effects 0.000 claims description 5
- 235000019871 vegetable fat Nutrition 0.000 claims description 5
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 4
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 4
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 claims description 4
- 241001608472 Bifidobacterium longum Species 0.000 claims description 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 36
- 241000186000 Bifidobacterium Species 0.000 description 26
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 19
- 230000012010 growth Effects 0.000 description 17
- 230000009286 beneficial effect Effects 0.000 description 16
- 239000000126 substance Substances 0.000 description 15
- 230000036541 health Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 230000036039 immunity Effects 0.000 description 12
- 235000013336 milk Nutrition 0.000 description 12
- 239000008267 milk Substances 0.000 description 12
- 210000004080 milk Anatomy 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 239000002994 raw material Substances 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 239000004310 lactic acid Substances 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 241000186660 Lactobacillus Species 0.000 description 6
- 235000013365 dairy product Nutrition 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 150000002482 oligosaccharides Chemical class 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 201000010538 Lactose Intolerance Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 3
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000015895 biscuits Nutrition 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000021022 fresh fruits Nutrition 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000001477 organic nitrogen group Chemical group 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010052764 Fructose-6-phosphate phosphoketolase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 108010066657 azoreductase Proteins 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 230000001847 bifidogenic effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 208000011140 intestinal infectious disease Diseases 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 108010042648 lactocin Proteins 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000009063 long-term regulation Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 239000003895 organic fertilizer Substances 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 229940074386 skatole Drugs 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000021127 solid diet Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 206010046947 vaginismus Diseases 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于复合益生菌固体饮料。具体地说,是针对存在便秘症状人群的体质特征,由多种益生菌共同组成的复合益生菌和谷物等多重天然植物精华进行合理搭配,从而达到调理肠道环境,改善便秘症状效果的一款固体饮料。
Description
技术领域
本发明属于复合益生菌固体饮料。具体地说,是针对存在便秘症状人群的体质特征,由多种益生菌共同组成的复合益生菌和谷物等多重天然植物精华进行合理搭配,从而达到调理肠道环境,改善便秘症状效果的一款固体饮料。
背景技术
便秘是临床常见的复杂症状,而不是一种疾病,主要是指排便次数减少、粪便量减少、粪便干结、排便费力等。虽然便秘属于一种症状,并不是一种独立的疾病,但对人体造成的危害却不小。有科学依据表明便秘会引起胃肠神经功能紊乱;形成粪便溃疡;患结肠癌;诱发心、脑血管疾病发作;引起肛肠疾患;易使妇女发生痛经,阴道痉挛,并生产尿潴留,尿路感染等症状;影响大脑功能等。
肠道健康的第一步就是要保护好我们肠道内的细菌,肠道内的菌群分为益生菌、中性菌和有害菌三种。
正常情况下,胃肠道中绝大多数细菌是对人体有益的,称之为“益生菌”,可以帮我们消化乳糖、降解并排泄多余胆固醇;为我们的机体提供维生素B族,刺激免疫器官发育,并促使其功能不断地演进、完善,有益人体健康。益生菌与我们的胃肠道黏膜共同筑成了一道生态屏障,抵御和抗击各种外来的病原微生物。
有研究指出,体魄强健的人肠道内有益菌的比例达到70%,普通人则是25%,便秘人群减少到15%,而癌症病人肠道内的益生菌的比例只有10%。益生菌和有害菌的关系是此消彼长,肠内就那么多空间容纳这些菌,益生菌多了,有害菌就减少。所以人体肠道内益生菌的比例越高,微生态环境就越好,肠道就越显年轻有活力。肠道的健康不仅体现在消化吸收良好、大便正常和不易感染肠道疾病;对全身而言,充足的、有活力的益生菌通过抑制各种有害菌,减少了体内毒素的生成,减轻了肝脏解毒负担。所以说改善肠道健康,补充益生菌很重要。
几十年来,在3000多项关于益生菌的临床研究中几乎没有副作用报道的同时,很多研究表明:益生菌有助于肠道维持长期的健康生态,对腹痛、腹泻、便秘等有长效的调节作用。
缓解乳糖不耐症状。益生菌能够帮助身体摄入的营养物质在肠道内快速消化,将乳糖分解成乳酸,减轻乳糖不耐症状。双歧杆菌和乳酸杆菌不但能产生各种维生素,烟酸和叶酸供机体所需,还能抑制某些维生素分解菌,来保证维生素的供应;此外,双歧杆菌还能够帮助改善肝功能,降低血氨。
调整微生态失调,防腹泻 。活着的益生菌进入人体肠道之后,通过生长和代谢作用来促进肠道中细菌群的正常化,抑制肠道内腐败物质产生,保持肠道机能正常。能够有效预防细菌性进行肠炎,痢疾,便秘等症状。还有一部分益生菌有抗胃酸的功效,益生菌依附在胃壁上皮细胞表面,通过代谢活动来抑制幽门螺杆菌生长,预防胃溃疡发生。
增强人体免疫力。益生菌能产生过氧化氢,有机酸,细菌素,游离脂肪酸等物质来抑制有害细菌滋生;当益生菌定植于粘膜,皮肤表面或细胞之间时,能生成生物屏障来阻止病原微生物的定殖,起到和有害细菌争夺营养,互利共生和抵抗作用,并且能刺激机体的非特异性免疫功能,增强肠道免疫球蛋白分泌,改善肠道屏障功能。
降低血清胆固醇。益生菌降低血清胆固醇可能与调节利用内源性代谢产物,加速短链脂肪酸代谢有关系。服用双歧杆菌,乳酸杆菌的生物制剂,能够使胆固醇转化成人体不会吸收的粪甾醇类物质,来达到降低血清胆固醇的目的。
缓解过敏作用。过敏主要是由于人体免疫功能失调出现不平衡的现象。当过敏体质的人群受到外来物质或生物体刺激免疫系统,产生过多免疫球蛋白,释放出一种叫组织胺的物质,从而引发过敏症状。益生菌能起到调节体内免疫球蛋白抗体,有效缓解过敏症状的功效。
预防阴道感染。很多益生菌都能起到酸化泌尿生殖道的功效,它可以通过降低阴道内PH值来抑制有害细菌的生长,并通过与有害细菌争夺生存空间和资源来遏制有害细菌的滋生。
防治高血压。乳酸菌产生的某些物质具有减低血压的功效,还有的益生菌能特意分解乳蛋白,产生抑制引起血压上升的酶活性多肽,常饮用含有活性多肽的酸奶能够起到防治高血压的功效。
预防癌症,抑制肿瘤生长。益生菌能够起到抑制肠道中某些酶的活性的作用,如尿素,消极还原酶,偶氮还原酶等,这些酶能参与肠道中致癌物质生成;胆盐经肠道遇到有害细菌发生接力,也会导致致癌物产生,引起肠癌。使用益生菌除了能够提高巨噬细胞的活性防止肿瘤生长之外,还能抑制有害细菌,降低致癌率。
每一种益生菌都有自己独特的功效,将多种益生菌相结合组成的复合益生菌功效比单一的一种要好很多,尤其是对于肠胃的健康方面。有很好的调节保护作用。随着生活节奏加快,工作压力的影响等等,我们很多人都多多少少存在胃肠道方面的疾病,补充复合益生菌可以有效的帮助我们调节肠胃,减少疾病的发病率。综上所述,由多种益生菌共同组成的复合益生菌是调理肠道环境,改善便秘症状效果的合理选择。
发明内容
本发明是一款调理肠道环境,改善便秘症状效果的固体饮料,通过多种益生菌共同组成的复合益生菌和谷物等多重天然植物精华进行合理搭配,达到调理肠道环境,改善便秘症状的效果,并且效果显著。
本发明主要用于改善便秘症状,其特征在于复合益生菌与谷物等天然成分的组合形式,总质量10g,按照以下重量分数的配制:果蔬粉30%,花生粉20%,植物脂肪粉10%,低聚麦芽糖15%,低聚木糖10%,低聚半乳糖10%,益生菌活菌数高于100亿cfu。
制备方法是按照上述重量分数准确称取原料,按比例选取粉碎,混合均匀。
本发明原料及原理分析:
复合益生菌大家都不陌生,它是由多种益生菌共同组成的,每一种益生菌都有自己独特的功效,将多种益生菌相结合组成的复合益生菌功效比单一的一种要好很多,尤其是对于肠胃的健康方面。有很好的调节保护作用。随着生活节奏加快,工作压力的影响等等,我们很多人都多多少少存在胃肠道方面的疾病,补充复合益生菌可以有效的帮助我们调节肠胃,减少疾病的发病率:
①帮助营养物质的消化吸收许多益生菌株在胃肠道内可产生消化酶这些酶可帮助人体更好地消化所摄入的食品及吸收食品中的营养成分。益生菌还可竞争性抑制有害微生物吸收营养物质及进入血液循环系统。嗜酸乳杆菌是这方面的代表菌株可分泌消化乳糖的乳糖酶从而缓解乳糖不耐症。
②产生重要的营养物质:益生菌能产生维生素包括泛酸、尼克酸、B1,B2,B6及维生素K等同时能产生短链脂肪酸、抗氧化剂、氨基酸等等对骨骼成长和心脏健康有重要作用。
③抵抗细菌病毒的感染提升免疫通过三大步骤益生菌可清除有害菌对身体的伤害:抑制有害菌的生长。益生菌通过产生杀灭有害菌的化学物质及与有害菌竞争空间和资源而遏制它们的生长;抑制有害菌产生毒素;清除有害菌产生的毒素;预防和治疗某些疾病如肠道综合症、呼吸道感染 、生殖系统感染、过敏、口臭、胃溃疡等。
以上是关于复合益生菌功效的相关介绍,长期处于高压力下,作息不正常者,或饮食偏向高脂高热量者,有害菌会利用肠道内无法完全消化的蛋白质与脂肪来繁殖。补充八益菌能有效帮助健胃整肠,同时促进肠胃蠕动,将体内产生的宿便排出,达到自然减肥及维持健康的效果。
多种益生菌对便秘都具有良好的的调节和改善作用,本发明引入多种双歧杆菌、乳杆菌以及一些天然植物精华。本发明原料包含花生粉、果蔬粉、植物脂肪粉、低聚麦芽糖、低聚木糖、低聚半乳糖、乳双歧杆菌、长双歧杆菌、青春双歧杆菌、鼠李糖乳杆菌、嗜酸乳杆菌、干酪乳杆菌。
双歧杆菌是一个细菌属名。双歧杆菌属(Bifidobacterium)是一种革兰氏阳性、不运动、细胞呈杆状、一端有时呈分叉状、严格厌氧的细菌属,广泛存在于人和动物的消化道、阴道和口腔等生境中。双歧杆菌属的细菌是人和动物肠道菌群的重要组成成员之一。一些双歧杆菌的菌株可以作为益生菌而用在食品、医药和饲料方面。双歧杆菌革兰氏染色阳性,细胞形态多样,包括短杆状、近球状、长弯杆状、分叉杆状、棍棒状或匙状。细胞单个或排列成V形、栅栏状、星状。不抗酸、不形成芽孢,不运动。专性厌氧。菌落较小、光滑、凸圆、边缘完整,呈乳脂色至白色。最适生长温度为37-41℃,最低生长温度为25-28℃,最高为43-45℃。初始生长最适pH为6.5-7.0,生长pH范围一般为 4.5-8.5。糖代谢经独特异型乳酸发酵的双歧杆菌途径进行,特点是利用葡萄糖产乙酸和乳酸(摩尔比3:2),不产生二氧化碳,其中果糖-6-磷酸盐磷酸转酮酶是关键酶,在分类鉴定中,可用以区分与双歧杆菌近似的几个属。过氧化氢酶阴性(少数例外);不还原硝酸盐。氮源通常为铵盐,少数为有机氮。对氯霉素、林肯霉素、四环素、青霉素、万古霉素、红霉素和杆菌肽等抗生素敏感,对多粘菌素B、卡那霉素、庆大霉素、链霉素和新霉素不敏感。G + C mol%值为55-67。模式种是两歧双歧杆菌(Bifidobacteriumbifidus)。
两歧双歧杆菌、青春双歧杆菌(B. adolescentis)、婴儿双歧杆菌(B. infantis)、长双双歧杆菌是一种重要的肠道有益微生物。双歧杆菌作为一种生理性有益菌,对人体健康具有生物屏障、营养作用、抗肿瘤作用、免疫增强作用、改善胃肠道功能、抗衰老等多种重要的生理功能 。人体肠道中定植着大量的微生物。肠道微生物与人体健康与疾病之间存在着十分密切的关系。根据目前所知道的肠道微生物对人体健康的影响,肠道微生物可分为有益、无害和有害3大类。在正常情况下,人体内的肠道微生物形成了一个相对平衡的状态。一旦平衡受到破坏,如服用抗生素、放疗、化疗、情绪压抑、身体衰弱、缺乏免疫力等,就会导致肠道菌群失去平衡,某些肠道微生物如产气荚膜梭菌等在肠道中过度增殖并产生氨、胺类、硫化氢、粪臭素、吲哚、亚硝酸盐、细菌毒素等有害物质,从而进一步影响机体的健康。
双歧杆菌可以通过调整肠道菌群,并通过产生乙酸、乳酸等短链脂肪酸来抑制肠道腐败菌的生长和有毒代谢产物的形成,刺激肠蠕动,从而减少水分的过度吸收而缓解便秘症状。
乳杆菌是细菌的一科,为革兰氏染色阳性、无芽孢杆菌。乳酸菌在自然界中分布很广,在植物体表、乳制品、肉制品、啤酒、葡萄酒、果汁、麦芽汁、发酵面团、污水以及人畜粪便中,均可分离到。中国传统的食品,如泡菜、榨菜、腌菜和酿酒等的制作保藏技术就是利用了乳酸菌的这一作用。对肠道及吸收好。
干酪乳杆菌(Lactobacillus casei)属于乳杆菌属(Lactobacillus),是革兰氏阳性菌,不产芽孢,无鞭毛,不运动,兼性异型发酵乳糖,不液化明胶;最适生长温度为37℃,G+C含量为45.6%~47.2%;菌体长短不一,两端呈方形,常成链;菌落粗糙,灰白色,有时呈微黄色,能发酵多种糖。干酪乳杆菌存在于人的口腔、肠道内含物和大便及阴道中,也常常出现在牛奶和干酪、乳制品、饲料、面团和垃圾中。
干酪乳杆菌作为益生菌的一种,能够耐受有机体的防御机制,其中包括口腔中的酶、胃液中低PH值和小肠的胆汁酸等。所以干酪乳杆菌进入人体后可以在肠道内大量存活,起到调节肠内菌群平衡、促进人体消化吸收等作用。同时,干酪乳杆菌具有高效降血压、降胆固醇,促进细胞分裂,产生抗体免疫,增强人体免疫及预防癌症和抑制肿瘤生长等功能;还具有缓解乳糖不耐症、过敏等益生保健作用。由于干酪乳杆菌对其宿主营养、免疫、防病等具有显著的益生功效,越来越成为人们研究、开发、生产的焦点。随着高血压人群的增加,对干酪乳杆菌的研究以及用其开发功能性乳制品具有重要意义。
鼠李糖乳杆菌(L.rhamnosus),从属于乳杆菌属,是人体正常菌群之一,肠道黏着率高,定植能力强,并具有高效降胆固醇,促进细胞分裂,可起到调节肠道菌群、预防和治疗腹泻、排除毒素、预防龋齿、提高机体免疫力及抗癌等重要的生理保健功能。相对于双歧杆菌,更容易在肠道定植。鼠李糖杆菌有调节肠道菌群、促进双歧杆菌生长及发挥作用的功能;有助于止泻;有利于促进机体毒素排出、增强机体抵抗力;有利于过敏体质的调节;通过提高免疫力从而达到预防感冒的功效。相对于其他益生菌,鼠李糖杆菌生产环境要求比较宽松,有很好的耐酸、耐氧的特点。
嗜酸乳杆菌不仅在胃中,它还是人体小肠内的主要益生菌。 在胃中能存活的致病菌的胃部是个小型"消毒车间",这是由于胃液具有很强的酸性。调整肠道菌群平衡,抑制肠道不良微生物的增殖。嗜酸乳杆菌对致病微生物具有拈抗作用。嗜酸乳杆菌能分泌抗生物素类物质(嗜酸乳菌素(acidolin)、嗜酸杆菌素(acidophilin)、乳酸菌素(1aetocidon)),对肠道致病菌产生的拮抗作用。嗜酸乳杆菌(Lactobacillusacidophilus,简称A)和双歧乳杆菌(Bifidobacterium,简称B)混合组成的发酵剂(肽胃舒益生菌)。摄入含有这两种活菌的乳食品对消化器官有好处,特别是对胃肠功能失调的婴幼儿和一些长期口服抗菌素而引起胃肠功能失调的病人,食用含有这两种活菌的发酵乳后,可以迅速使肠道内的菌群恢复正常平衡,抑制腐败菌的增殖,所以具有很好的营养保健作用。一提到双歧杆菌,很多人都知道,它是大肠中的主要益生菌;而嗜酸乳杆菌不仅在胃中,它还是人体小肠内的主要益生菌。此二者数量庞大,相互扶助,通过维护整个胃肠道的微生态平衡,起到促进人体健康的作用。
一提到双歧杆菌,很多人都知道,它是大肠中的主要益生菌;而嗜酸乳杆菌不仅在胃中,它还是人体小肠内的主要益生菌。此二者数量庞大,相互扶助,通过维护整个胃肠道的微生态平衡,起到促进人体健康的作用。嗜酸乳杆菌在人体整个胃肠道中,"从上而下"调节微生态环境。"下"是指在大肠中,它们也可以释放有益双歧杆菌等其他益生菌生长的物质,增加大肠内益生菌的数量、增强它们的生命力。人体肠道内益生菌的比例越高,微生态环境就越好,肠道就越显年轻有活力。肠道的健康不仅体现在消化吸收良好、大便正常和不易感染肠道疾病;对全身而言,充足的、有活力的益生菌通过抑制各种有害菌,减少了体内毒素的生成,减轻了肝脏解毒负担;双歧杆菌和嗜酸乳杆菌在肠道内发酵后,还可产生乳酸和醋酸,能提高钙、磷、铁的利用率,促进铁和维生素D的吸收,产生维生素K及维生素B,还可以减少胆固醇的吸收,并能降低辐射对人体的伤害。
果蔬粉,是将新鲜水果、蔬菜经过具有国际先进水平的冻干技术和设备,经预处理、速冻、真空干燥、紫外线杀菌、包装贮存等10多道工序加工而成。在和其它物质搭配时,因其水分含量低,所以可以延长产品贮藏期,降低贮藏、运输、包装等费用,同时原料的利用率高,对原料的要求不高。因为果蔬粉是用多种的新鲜水果蔬菜进行提纯所制作而成,所以果蔬粉其中含有大量的微量元素以及多种矿物质,经常食用对身体非常好,而且食用果蔬粉可以预防身体高血压,或者是身体肥胖等,还可以促进身体的新陈代谢,对身体有很大的好处,而且还可以缓解便秘等作用,口感也非常好。研究表明,果蔬粉几乎能应用到食品加工的各个领域,可用于提高产品的营养成分,改善产品的色泽和风味等。
花生粉,是花生仁榨油后的残渣经烘干、粉碎后制成的粉状物。花生粉是供微生物生长的有机氮源之一,含有丰富的蛋白质、微量元素,也含少量的花生油。从花生的营养角度来讲,花生仁富含亚油酸等人体必需的不饱和脂肪酸,特别有利于人体的吸收和消化作用,亚油酸在人体内不能合成,但对调节人体的生理机能,促进生长发育,降解胆固醇,预防高血压和动脉粥状硬化具有重要作用。花生蛋白质的氨基酸较完全,其含量高于动物蛋白,且不含胆固醇,是优质植物蛋白。花生米由整个的到磨成粉,只是形态的变化,是一种物理变化(就像冰化成了水),并不会影响其性质和原有营养。花生米的皮对于贫血、血小板减少的人来说,有辅助治疗的作用。所以,民间有花生衣补血的说法。从消化吸收的角度来说,磨碎的、流质的食物,比完整的、固体的食物容易消化吸收,因为缩短了胃的消化过程。从口感上说,当然是完整的、固体的更好吃,具备了原有食物的特点。
植物脂肪粉,是经乳化处理的植脂末,具有良好的溶解性、乳化分散性,并在水中形成均匀奶状液,因此它可作任意比例的粉液混合;它能改善食品内部组织,增香脂肪,使口感细腻、润滑、厚实及更富"奶味",故又是咖啡制品的好伴侣,可用于速溶麦片、蛋糕、饼干等,使蛋糕组织细腻,保持湿润,提高弹性。饼干可提高起酥性,不易走油等。植脂本由于其混溶性好,"奶感"强,在某些食品加工中可替代奶粉或减少奶粉的用量,从而在保持产品品质的前提下降低用料成本,如在冰淇淋,速溶奶粉,某些含乳饮料等。植脂末速溶性好,"奶"味强,在食品加工中可以代替奶粉或减少用奶量,从而在保持产品品质稳定的前提下,可降低生产成本。所以其优点包括脂肪含量可随意调整,范围在5%-75%之间,油脂品种也可根据需要随意选择;功能性质(水溶性、乳化性、发泡性)优良,可发满足不同食品领域的加工需要;风味多样,产品可进行调香、调色、调味处理或强化维生素微量元素;微胶囊化产品更易储存,不易氧化,稳定性好,风味不易散失;可替代昂贵的牛奶脂肪、可可脂肪或部分乳蛋白,降低成本。
低聚麦芽糖,具有易消化、低甜度、低渗透特性,可延长供能时间,增强肌体耐力,抗疲劳等功能,人体经过重(或大)体力消耗和长时间的剧烈运动后易出现脱水,能源储备,消耗血糖降低,体温高,肌肉神经传导受影响,脑功能紊乱等一系列生理变化和症状,而食用低聚麦芽糖后,不仅能保持血糖水平,减少血乳酸的产生,而且胰岛素分泌平衡,人体试验证明,使用低聚糖后耐力和功能力可增加30%以上,功效非常明显。低聚异麦芽糖是采用优质淀粉为原料,通过酶的作用,经过液化、浓缩、干燥等一系列工序精制而成的以低聚异麦芽糖为主要成份的白色粉末状淀粉糖制品。低聚异麦芽糖粉是人体肠道内有益健康的双歧杆菌的繁殖因子,能促进有益菌群在肠繁殖。双歧杆菌是最主要的有益菌,它能抑制人体肠内有害的繁殖及有害物质的产生,防止便秘,增强免疫力,降低血脂和胆固醇等方面的功效,适用于保健品、饮料、乳制品、糖果、饼干小食品及焙烤食品。低聚异麦芽糖味质美好,可用来代替部分蔗糖,减低食品甜度与改善其味质,对于糖果、糕点等的组织与物性无不良影响。低聚异麦芽糖粉的耐热,耐酸性极佳,在PH3、120℃之下长时间加热不会分解,应用到饮料、罐头及高温处理或PH值食品中可保持其特性和功能。低聚异麦芽糖保持水分不易蒸发,对各类食品的湿润及品质的维持效果好并能抑制蔗糖和葡萄糖的结晶形成,对稍存放即硬化的食品能防止淀粉老化,而延长保存时间。低聚异麦芽糖的冰点下降与蔗糖接近,冻结温度高于果糖,添加到面包、发酵乳、酸奶中,不会被酵母菌、乳酸菌利用掉而残留在食品中,发挥各种特性,促进双歧杆菌发育,不妨碍正常的乳酸菌发挥功效。
低聚木糖,又称木寡糖,是由2-7个木糖分子以β-1,4糖苷键结合而成的功能性聚合糖。与通常人们所用的大豆低聚糖、低聚果糖、低聚异麦芽糖等相比具有独特的优势,它可以选择性地促进肠道双歧杆菌的增殖活性。其双歧因子功能是其它聚合糖类的10-20倍。低聚木糖很难为人体消化酶所分解,用唾液、胃液、胰液和小肠酶液进行的消化实验表明:各种消化液几乎都不能分解低聚木糖,它的能量值几乎为零,既不影响血糖浓度,也不增加血糖中胰岛素水平,并且不会形成脂肪沉积,故可在低能量食品中发挥作用,最大限度地满足了那些喜爱甜品而又担心糖尿病和肥胖的人的要求,因此糖尿病人、肥胖病人和低血糖病人均可放心食用。酸、热稳定性好,难发酵,与其他低聚糖相比,低聚木糖的突出特点是稳定性非常好。即使在酸性条件下(PH=2.5-7)加热至100℃也基本不分解,而某些功能性低聚糖在酸性条件下则很容易分解,从而其促进双歧杆菌增殖活性降低。有效摄入量少。
低聚半乳糖(Galactooligosaccharides,GOS)是一种具有天然属性的功能性低聚糖,其分子结构一般是在半乳糖或葡萄糖分子上连接1~7 个半乳糖基,即Gal-(Gal)n-Glc/Gal(n 为0-6)。在自然界中,动物的乳汁中存在微量的GOS,而人母乳中含量较多,婴儿体内的双歧杆菌菌群的建立很大程度上依赖母乳中的GOS 成分。低聚半乳糖作为一种新的功能性食品,在我国将具有广阔的市场前景。这是在中国发酵工业协会、中国食品添加剂生产应用协会和科特(中国)有限公司、日本公司联合主办的"低聚半乳糖研讨会"上获悉的。低聚糖在我国还是一个新兴行业,能达到上千吨生产规模的只有低聚异麦糖和低聚果糖,低聚半乳糖还尚未成规模。据权威人士分析,低聚半乳糖在中国有很大的市场。但由于我们在这方面的研究开发、宣传推广的时间还不太长,真正了解低聚半乳糖的人很少。广大消费者对它也还需要一个认识和接受的过程。中国食品行业对此重视,在"九五"和"十五"规划中都提出把开发满足不同消费人群需要的保健食品作为发展的重点。可以相信通过努力,各种含有低聚半乳糖的食品将会更多地出现在人们餐桌上。
附图说明
图1是实施案例1所制备的粉末形态的示意图。
图2是实施案例1所制备的产品包装的示意图。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例1:总质量10g,按照以下重量分数的配制:果蔬粉30%,花生粉20%,植物脂肪粉10%,低聚麦芽糖15%,低聚木糖10%,低聚半乳糖10%,益生菌活菌数高于100亿cfu。
制备方法是按照上述重量分数准确称取原料,按比例选取粉碎,混合均匀。
制成的粉末每包10g。服用打开包装袋后,将内容物倒入口中,用温水服下。一天一次,一次一包,时间随意。
实施例2:按照固定比例制得粉末产品,包装使用。制得的粉末形态和产品的包装,如图1、图2所示。
Claims (7)
1.一种复合益生菌固体饮料,其特征是针对存在便秘症状人群的体质特征,由多种益生菌共同组成的复合益生菌和谷物等多重天然植物精华进行合理搭配,从而达到调理肠道环境,改善便秘症状效果的一款固体饮料。
2.本发明调理肠道环境,改善便秘症状,其特征在于由多种益生菌共同组成的复合益生菌和谷物等多重天然植物精华进行合理搭配,按照以下重量分数的配制:果蔬粉30%,花生粉20%,植物脂肪粉10%,低聚麦芽糖15%,低聚木糖10%,低聚半乳糖10%,益生菌活菌数高于100亿cfu。
3.根据权利要求1所述的方法,其特征在于,多种益生菌共同组成的复合益生菌和谷物等多重天然植物精华进行合理搭配,从而达到调理肠道环境,改善便秘症状的效果。
4.根据权利要求1所述的方法,其特征在于,所述益生菌为乳双歧杆菌、长双歧杆菌、青春双歧杆菌、鼠李糖乳杆菌、嗜酸乳杆菌、干酪乳杆菌等量混合。
5.根据权利要求1所述的方法,其特征在于,制成的便秘改善、肠道调理的产品包括,但不限于食品、特殊医学用途配方食品、医学配方食品、保健品和药品形式,也可以是其他产品形式。
6.由该配方或相近配方制成的固体饮料,在改善肠道情况中的应用。
7.由该配方或相近配方制成的固体饮料,在调节便秘症状中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010281907.5A CN111587975A (zh) | 2020-04-11 | 2020-04-11 | 一种改善便秘症状的固体饮料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010281907.5A CN111587975A (zh) | 2020-04-11 | 2020-04-11 | 一种改善便秘症状的固体饮料 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111587975A true CN111587975A (zh) | 2020-08-28 |
Family
ID=72180083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010281907.5A Pending CN111587975A (zh) | 2020-04-11 | 2020-04-11 | 一种改善便秘症状的固体饮料 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111587975A (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104720066A (zh) * | 2013-12-18 | 2015-06-24 | 天津畅润华生物科技有限公司 | 复合益生菌固体饮料 |
CN105394181A (zh) * | 2015-10-27 | 2016-03-16 | 江西美庐乳业集团有限公司 | 一种改善便秘、帮助维持肠道健康的营养包 |
CN105661245A (zh) * | 2016-01-29 | 2016-06-15 | 江苏微康生物科技有限公司 | 一种益生菌型果蔬酵素固体饮料 |
CN106173772A (zh) * | 2016-07-06 | 2016-12-07 | 慧谷生命科技湖北有限公司 | 一种蔬果酵素固体饮料及其制备方法 |
CN106954847A (zh) * | 2017-03-30 | 2017-07-18 | 广州能靓生物技术有限公司 | 具有润肠通便功能的酵素益生菌组合物、应用及加工制剂 |
CN108902628A (zh) * | 2018-07-20 | 2018-11-30 | 殷金玲 | 一种儿童抗炎益生菌固体饮料 |
CN108935679A (zh) * | 2018-07-04 | 2018-12-07 | 江西颐迪科技有限公司 | 一种即冲即食酸奶固体饮品及其制备方法 |
CN109497386A (zh) * | 2018-12-26 | 2019-03-22 | 厦门泰好保健食品有限公司 | 一种改善肠道消化的植物固体饮料组合 |
CN110150525A (zh) * | 2018-02-01 | 2019-08-23 | 岳壮斌 | 一种益生菌固定饮料及其制备方法 |
CN110692885A (zh) * | 2019-11-13 | 2020-01-17 | 上海英库商务咨询有限公司 | 一种用于缓解便秘的益生菌保健饮料 |
-
2020
- 2020-04-11 CN CN202010281907.5A patent/CN111587975A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104720066A (zh) * | 2013-12-18 | 2015-06-24 | 天津畅润华生物科技有限公司 | 复合益生菌固体饮料 |
CN105394181A (zh) * | 2015-10-27 | 2016-03-16 | 江西美庐乳业集团有限公司 | 一种改善便秘、帮助维持肠道健康的营养包 |
CN105661245A (zh) * | 2016-01-29 | 2016-06-15 | 江苏微康生物科技有限公司 | 一种益生菌型果蔬酵素固体饮料 |
CN106173772A (zh) * | 2016-07-06 | 2016-12-07 | 慧谷生命科技湖北有限公司 | 一种蔬果酵素固体饮料及其制备方法 |
CN106954847A (zh) * | 2017-03-30 | 2017-07-18 | 广州能靓生物技术有限公司 | 具有润肠通便功能的酵素益生菌组合物、应用及加工制剂 |
CN110150525A (zh) * | 2018-02-01 | 2019-08-23 | 岳壮斌 | 一种益生菌固定饮料及其制备方法 |
CN108935679A (zh) * | 2018-07-04 | 2018-12-07 | 江西颐迪科技有限公司 | 一种即冲即食酸奶固体饮品及其制备方法 |
CN108902628A (zh) * | 2018-07-20 | 2018-11-30 | 殷金玲 | 一种儿童抗炎益生菌固体饮料 |
CN109497386A (zh) * | 2018-12-26 | 2019-03-22 | 厦门泰好保健食品有限公司 | 一种改善肠道消化的植物固体饮料组合 |
CN110692885A (zh) * | 2019-11-13 | 2020-01-17 | 上海英库商务咨询有限公司 | 一种用于缓解便秘的益生菌保健饮料 |
Non-Patent Citations (1)
Title |
---|
陈琳等: "老年人肠道功能性固体饮料的工艺研究", 《食品工业》, vol. 38, no. 12, 20 December 2017 (2017-12-20), pages 97 - 100 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Prado et al. | Trends in non-dairy probiotic beverages | |
CN1802101B (zh) | 异麦芽酮糖醇(1,6gps和1,1gpm混合物)作为生产用于治疗肠道疾病的药物及其他用途的益生元的应用 | |
US8551543B2 (en) | Symbiotic maple product compositions and methods | |
HU228050B1 (en) | Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain | |
CN113826692A (zh) | 一种益生菌固体饮料及其制备方法 | |
CN103653170A (zh) | 一种水苏糖益生菌固体饮料 | |
Caramia et al. | Probiotics: from the ancient wisdom to the actual therapeutical and nutraceutical perspective | |
CN106954856A (zh) | 一种酵素膳食纤维及其制备工艺 | |
CN107647410A (zh) | 一种复合配比的益生菌粉及其制备方法 | |
CN102300472A (zh) | 共生组合物及其制备方法 | |
JP4336930B2 (ja) | 乳酸菌発酵液の製造方法及び該発酵液を原料とする食品 | |
Sip et al. | Probiotics and prebiotics | |
KR101884634B1 (ko) | 체중 조절 효과를 지닌 유산균 발효액 | |
CN108795823A (zh) | 一种改善女性孕产妇肠道菌群的益生菌的培养方法和应用 | |
CN101574375B (zh) | 一种乳酸菌保健胶囊及其制备方法 | |
CN111587975A (zh) | 一种改善便秘症状的固体饮料 | |
KR102685688B1 (ko) | 유산균 수정과의 제조방법 및 이에 따라 제조된 유산균 수정과 | |
KR102685690B1 (ko) | 유산균 식혜의 제조방법 및 이에 따라 제조된 유산균 식혜 | |
Hunter | Probiotic foods for good health: Yogurt, sauerkraut, and other beneficial fermented foods | |
JP2000026304A (ja) | ビフィズス菌による運動能力の向上 | |
Hernandez et al. | Development of probiotics and prebiotics | |
Hardy | Fact vs. Fiction: Fermented Foods and Gut Health | |
EP2628394B1 (en) | Probiotic functional food suitable for immunocompromised individuals undergoing treatment such as chemotherapy and/or radiotherapy | |
Chaturvedi et al. | Synbiotic Foods: Significance, Applications, and Acceptance | |
Kumar et al. | Composite Probiotic Dairy Products: Concepts and Design with a Focus on Millets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200828 |